abstract |
The invention provides a combination therapy comprising the administration of AMG252 and cytarabine or decitabine for the treatment of acute myelogenous leukemia. In addition, the invention relates to pharmaceutical compositions containing AMG252 and cytarabine or decitabine for the treatment of acute myelogenous leukemia. |